In a female patient with a hematocrit of 47.2% and a mean platelet volume of 11.2 fL, with otherwise normal laboratory results, what is the appropriate evaluation and management?

Evaluation and Management

This female patient with a hematocrit of 47.2% requires evaluation for polycythemia vera (PV), starting with serum erythropoietin (EPO) level and consideration of bone marrow examination with JAK2 mutation testing. The hematocrit exceeds the sex-specific threshold that warrants investigation, particularly given NCCN guidelines noting that a lower hematocrit cutoff of 42% may be appropriate for female patients 1.

Initial Diagnostic Approach

The hematocrit of 47.2% in a female patient meets criteria for PV evaluation. According to established diagnostic algorithms, PV should be suspected when 2:

• Hemoglobin/hematocrit is above the 95th percentile adjusted for sex and race
• There is documented increase above baseline for the individual patient
• A PV-related feature accompanies borderline-high hematocrit

The mean platelet volume of 11.2 fL is at the upper end of normal (normal range 7.2-11.7 fL per large epidemiologic studies) 3, which is non-specific but does not exclude PV, as platelet indices can be variable in myeloproliferative neoplasms.

Recommended Diagnostic Workup

Step 1: Serum EPO Level

Order serum EPO immediately. In PV, EPO levels are typically low (specificity >90%), though sensitivity is only ~70% 2. A low or normal EPO level warrants further investigation, while an elevated EPO makes PV unlikely and suggests secondary causes.

Step 2: Bone Marrow Examination

If EPO is low or normal, proceed with bone marrow biopsy and aspirate with 2:

• Histologic examination (looking for hypercellularity, megakaryocyte proliferation, decreased iron stores)
• Cytogenetic studies
• JAK2 V617F mutation testing (present in majority of PV cases)

Step 3: Exclude Secondary Causes

Evaluate for conditions causing secondary erythrocytosis:

• Smoking history
• Chronic hypoxia (sleep apnea, lung disease, high altitude)
• Renal pathology (tumors, cysts)
• Testosterone or erythropoietin use

Management If PV Confirmed

Risk Stratification

Determine risk category based on 1:

• Low-risk: Age <60 years AND no prior thrombosis
• High-risk: Age ≥60 years OR prior thrombosis history

Treatment Algorithm

For Low-Risk PV (if patient is <60 years with no thrombosis history):

• Phlebotomy to maintain hematocrit <42% (sex-specific target for females) 1
• Aspirin 81-100 mg daily for vascular symptoms
• Manage cardiovascular risk factors aggressively
• Monitor every 3-6 months for thrombosis, bleeding, or disease progression
• Do NOT initiate cytoreductive therapy unless symptomatic indications develop

For High-Risk PV (if patient is ≥60 years or has thrombosis history):

• Phlebotomy to maintain hematocrit <42% (female-specific target)
• Aspirin 81-100 mg daily
• Hydroxyurea as first-line cytoreductive therapy 1
• Consider interferons for younger patients or specific situations
• Monitor every 3-6 months

Critical Pitfalls to Avoid

1. Do not dismiss borderline-elevated hematocrit in females - The standard <45% target is based on studies with mixed populations; 42% may be more appropriate for women 1

2. Do not rely solely on red cell mass measurement - It misses PV patients at the left tail of distribution and adds cost without improving diagnostic accuracy 2

3. Do not overlook PV-related features - Even with "otherwise normal" labs, look for: microcytosis (iron deficiency from phlebotomy/bleeding), subtle splenomegaly, aquagenic pruritus, unusual thrombosis, or erythromelalgia 2

4. The MPV of 11.2 fL is non-contributory to PV diagnosis - While at upper normal range 3, it lacks specificity for myeloproliferative disorders and should not influence decision-making

Immediate Next Steps

1. Order serum EPO level
2. Obtain complete history focusing on: symptoms of hyperviscosity, pruritus (especially after bathing), prior thrombosis, cardiovascular risk factors, smoking, medication use
3. Physical examination for splenomegaly
4. If EPO low/normal: refer to hematology for bone marrow biopsy and JAK2 testing
5. Counsel on thrombosis risk and importance of cardiovascular risk factor modification